Cannara Biotech Inc (LOVE) - Cash Flow Conversion Efficiency

Latest as of November 2025: 0.072x

Based on the latest financial reports, Cannara Biotech Inc (LOVE) has a cash flow conversion efficiency ratio of 0.072x as of November 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$7.96 Million ≈ $5.76 Million USD) by net assets (CA$111.21 Million ≈ $80.45 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cannara Biotech Inc balance sheet independence to measure how much of total assets are equity-financed.

Cannara Biotech Inc - Cash Flow Conversion Efficiency Trend (2018–2025)

This chart illustrates how Cannara Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check LOVE cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Cannara Biotech Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cannara Biotech Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
John Hancock Income Securities Closed Fund NYSE:JHS	0.031x
Century Land Joint Stock Company VN:CRE	-0.006x
Lalin Property Public Company Limited BK:LALIN	-0.017x
C-Rad AB (publ) ST:CRAD-B	0.205x
InflaRx N.V F:IF0	-0.113x
ENIGMATIG LIMITED NYSE MKT:EGG	0.008x
LG Corp Preferred KO:003555	0.009x
Bulten AB ST:BULTEN	0.027x

Annual Cash Flow Conversion Efficiency for Cannara Biotech Inc (2018–2025)

The table below shows the annual cash flow conversion efficiency of Cannara Biotech Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see LOVE stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-08-31	CA$102.22 Million ≈ $73.95 Million	CA$20.01 Million ≈ $14.48 Million	0.196x	+61.19%
2024-08-31	CA$87.95 Million ≈ $63.62 Million	CA$10.68 Million ≈ $7.73 Million	0.121x	+63.86%
2023-08-31	CA$79.74 Million ≈ $57.69 Million	CA$5.91 Million ≈ $4.28 Million	0.074x	+181.38%
2022-08-31	CA$66.74 Million ≈ $48.28 Million	CA$-6.08 Million ≈ $-4.40 Million	-0.091x	-179.05%
2021-08-31	CA$64.12 Million ≈ $46.38 Million	CA$-2.09 Million ≈ $-1.51 Million	-0.033x	+86.57%
2020-08-31	CA$38.36 Million ≈ $27.75 Million	CA$-9.32 Million ≈ $-6.75 Million	-0.243x	-63.78%
2019-08-31	CA$49.93 Million ≈ $36.12 Million	CA$-7.41 Million ≈ $-5.36 Million	-0.148x	+5.07%
2018-08-31	CA$14.74 Million ≈ $10.66 Million	CA$-2.30 Million ≈ $-1.67 Million	-0.156x	--

About Cannara Biotech Inc

V:LOVE Canada Drug Manufacturers - Specialty & Generic

Market Cap

$126.80 Million

CA$175.28 Million CAD

Market Cap Rank

#18177 Global

#600 in Canada

Share Price

CA$1.83

Change (1 day)

-2.14%

52-Week Range

CA$1.58 - CA$1.98

All Time High

CA$3.05